Report Library
View More
Non-Small Cell Lung Cancer (NSCLC) ...
May 9, 2024
Renal Cell Carcinoma (RCC) KOL Inte...
May 7, 2024
Renal Cell Carcinoma (RCC) KOL Inte...
May 6, 2024
Renal Cell Carcinoma (RCC) KOL Inte...
May 3, 2024
Melanoma KOL Interview - US, Midwes...
April 30, 2024
Datamonitor Healthcare Infectious D...
April 29, 2024
Datamonitor Healthcare CV&Met Disea...
April 29, 2024
Datamonitor Healthcare I&I: Axial S...
April 29, 2024
Datamonitor Healthcare Infectious D...
April 29, 2024
Melanoma KOL Interview - Germany
April 26, 2024
Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 5/31/24 | Pfizer (PFE) | Lorbrena for Non-Small Cell Lung Cancer (NSCLC) | Subscribers Only | Subscribers Only | Subscribers Only |
| 5/31/24 | Gilead Sciences (GILD) | Trodelvy for Non-Small Cell Lung Cancer (NSCLC) | Subscribers Only | Subscribers Only | Subscribers Only |
| 5/31/24 | Novartis (NVS) | Scemblix for Chronic Myelogenous Leukemia (CML) | Subscribers Only | Subscribers Only | Subscribers Only |
| 5/31/24 | Lykos Therapeutics | Midomafetamine for Post-Traumatic Stress Disorder (PTSD) | Subscribers Only | Subscribers Only | Subscribers Only |
| 5/30/24 | Hengrui Pharmaceuticals (600276:SS) | Camrelizumab for Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 03/19/24 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 04/09/24 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 04/15/24 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
| 04/15/24 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
| 04/18/24 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |